✦ LIBER ✦

Response- and remission rates as efficacymarker of monotherapy with atypical neuroleptics in the treatment of acute mania

✍ Scribed by S. Eppendorfer; S. Wilhelm; C. Nicolay; H.P. Hundemer

Book ID: 118438681
Publisher: Elsevier Science
Year: 2007
Tongue: French
Weight: 44 KB
Volume: 22
Category: Article
ISSN: 0924-9338
DOI: 10.1016/j.eurpsy.2007.01.880

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The atypical neuroleptic, remoxipride, a

The atypical neuroleptic, remoxipride, and prolactin response in the treatment of acute schizophrenia

✍ Awad, A.G.; Lapierre, Y.D.; Jostell, K.-G.; Ancill, R.; Awad, A.G.; Bakish, D.; 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 95 KB

Rates of remission/euthymia with quetiap

Rates of remission/euthymia with quetiapine in combination with lithium/divalproex for the treatment of acute mania

✍ Norman Sussman; Jamie Mullen; Björn Paulsson; Mårten Vågerö 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 229 KB

P.3.d.021 Early improvement as a predict

P.3.d.021 Early improvement as a predictor of treatment response and remission in patients with acute schizophrenia: effects of asenapine

✍ Leucht, S.; Zhao, J. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Cost-effectiveness of atypical antipsych

Cost-effectiveness of atypical antipsychotics as treatment for patients with bipolar disorder (episodes of mania): A comparison between quetiapine, aripiprazole, olanzapine, risperidone and ziprasidone in the Russian health care

✍ Kulikov, A.; Komarov, I. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

Sorafenib As Monotherapy or in Associati

Sorafenib As Monotherapy or in Association With Cytarabine and Clofarabine for the Treatment of Relapsed/Refractory FLT3 ITD-Positive Advanced Acute Myeloid Leukemia

✍ Fontanelli, Giulia; Rocco, Melania; Caracciolo, Francesco; Benedetti, Edoardo; B 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 283 KB

Direct comparison of treatment responses

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

✍ Merete Lund Hetland; Ib Jarle Christensen; Ulrik Tarp; Lene Dreyer; Annette Hans 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views